Pharmafile Logo
Pharmafocus logo
Advanced Search

acadia

Showing 3 posts of 3 posts found.

schizophrenia

Acadia’s schizophrenia drug flops in Phase 3 trial

July 23, 2019
Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

News

US DoJ launch investigation into Acadia Pharmaceuticals

March 11, 2019
Sales and Marketing False Claims Act, SEC, acadia, antipsychotics, kickbacks

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …

News
acadia

FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug

March 30, 2016
Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024